JP2019528769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528769A5 JP2019528769A5 JP2019518049A JP2019518049A JP2019528769A5 JP 2019528769 A5 JP2019528769 A5 JP 2019528769A5 JP 2019518049 A JP2019518049 A JP 2019518049A JP 2019518049 A JP2019518049 A JP 2019518049A JP 2019528769 A5 JP2019528769 A5 JP 2019528769A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- human
- cell
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 9
- 239000013603 viral vector Substances 0.000 claims 8
- 101710163270 Nuclease Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 108020004511 Recombinant DNA Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000013607 AAV vector Substances 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 108091006106 transcriptional activators Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021083808A JP7106715B2 (ja) | 2016-10-04 | 2021-05-18 | 遺伝子改変細胞で使用するための共刺激ドメイン |
| JP2022112159A JP2022160443A (ja) | 2016-10-04 | 2022-07-13 | 遺伝子改変細胞で使用するための共刺激ドメイン |
| JP2024013162A JP2024059633A (ja) | 2016-10-04 | 2024-01-31 | 遺伝子改変細胞で使用するための共刺激ドメイン |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403880P | 2016-10-04 | 2016-10-04 | |
| US62/403,880 | 2016-10-04 | ||
| US201762501475P | 2017-05-04 | 2017-05-04 | |
| US62/501,475 | 2017-05-04 | ||
| US201762556199P | 2017-09-08 | 2017-09-08 | |
| US62/556,199 | 2017-09-08 | ||
| PCT/US2017/055133 WO2018067697A1 (en) | 2016-10-04 | 2017-10-04 | Co-stimulatory domains for use in genetically-modified cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083808A Division JP7106715B2 (ja) | 2016-10-04 | 2021-05-18 | 遺伝子改変細胞で使用するための共刺激ドメイン |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019528769A JP2019528769A (ja) | 2019-10-17 |
| JP2019528769A5 true JP2019528769A5 (enExample) | 2020-11-12 |
| JP6887492B2 JP6887492B2 (ja) | 2021-06-16 |
| JP6887492B6 JP6887492B6 (ja) | 2021-07-14 |
Family
ID=60382586
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518049A Active JP6887492B6 (ja) | 2016-10-04 | 2017-10-04 | 遺伝子改変細胞で使用するための共刺激ドメイン |
| JP2021083808A Active JP7106715B2 (ja) | 2016-10-04 | 2021-05-18 | 遺伝子改変細胞で使用するための共刺激ドメイン |
| JP2022112159A Pending JP2022160443A (ja) | 2016-10-04 | 2022-07-13 | 遺伝子改変細胞で使用するための共刺激ドメイン |
| JP2024013162A Pending JP2024059633A (ja) | 2016-10-04 | 2024-01-31 | 遺伝子改変細胞で使用するための共刺激ドメイン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083808A Active JP7106715B2 (ja) | 2016-10-04 | 2021-05-18 | 遺伝子改変細胞で使用するための共刺激ドメイン |
| JP2022112159A Pending JP2022160443A (ja) | 2016-10-04 | 2022-07-13 | 遺伝子改変細胞で使用するための共刺激ドメイン |
| JP2024013162A Pending JP2024059633A (ja) | 2016-10-04 | 2024-01-31 | 遺伝子改変細胞で使用するための共刺激ドメイン |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11286291B2 (enExample) |
| EP (3) | EP4115951A1 (enExample) |
| JP (4) | JP6887492B6 (enExample) |
| AU (4) | AU2017338846B2 (enExample) |
| CA (1) | CA3039014A1 (enExample) |
| DK (2) | DK3523326T3 (enExample) |
| ES (2) | ES2925644T3 (enExample) |
| WO (1) | WO2018067697A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016143389A (ru) | 2014-04-10 | 2018-05-15 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| AU2017338846B2 (en) * | 2016-10-04 | 2020-09-24 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
| CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
| WO2018201144A1 (en) * | 2017-04-28 | 2018-11-01 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| AU2018275894B2 (en) | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| US11434290B2 (en) * | 2017-06-08 | 2022-09-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with enhanced NFκB signaling |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| AU2020253538A1 (en) | 2019-04-03 | 2021-11-18 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) |
| US20220204994A1 (en) | 2019-04-05 | 2022-06-30 | Precision Biosciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| WO2021016608A1 (en) | 2019-07-25 | 2021-01-28 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| JP2022544825A (ja) | 2019-08-20 | 2022-10-21 | プレシジョン バイオサイエンシズ，インク． | 細胞免疫療法のためのリンパ球枯渇投与レジメン |
| WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| EP4069285A1 (en) | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells |
| JP7439279B2 (ja) * | 2020-02-13 | 2024-02-27 | イミュノファーム テクノロジー カンパニー リミテッド | キメラ抗原受容体の最適化 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| US20230192807A1 (en) * | 2020-05-15 | 2023-06-22 | Precision Biosciences, Inc. | Methods for immunotherapy |
| WO2021231954A1 (en) * | 2020-05-15 | 2021-11-18 | Precision Biosciences, Inc. | Methods for immunotherapy |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| IL299414A (en) * | 2020-06-30 | 2023-02-01 | Univ Court Univ Of Edinburgh | Transgene expression system |
| EP4192875A1 (en) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| US20230365995A1 (en) | 2020-10-07 | 2023-11-16 | Precision Biosciences, Inc. | Lipid nanoparticle compositions |
| EP4284823A1 (en) | 2021-01-28 | 2023-12-06 | Precision BioSciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| EP4355340A4 (en) * | 2021-06-16 | 2025-05-21 | Instil Bio, Inc. | RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY |
| WO2023064872A1 (en) | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| US20250009800A1 (en) | 2021-11-16 | 2025-01-09 | Precision Biosciences, Inc. | Methods for cancer immunotherapy |
| WO2023108150A1 (en) | 2021-12-10 | 2023-06-15 | Precision Biosciences, Inc. | Methods for cancer immunotherapy |
| IL313935A (en) | 2021-12-30 | 2024-08-01 | Tr1X Inc | CD4+ T cells expressing IL-10 chimeric antigen receptors and uses thereof |
| AU2024206812A1 (en) | 2023-01-05 | 2025-08-14 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| DE69534629D1 (de) | 1994-01-18 | 2005-12-29 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| USRE39229E1 (en) | 1994-08-20 | 2006-08-08 | Gendaq Limited | Binding proteins for recognition of DNA |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| JP4968498B2 (ja) | 2002-01-23 | 2012-07-04 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | ジンクフィンガーヌクレアーゼを用いる、標的化された染色体変異誘発 |
| AU2003218382B2 (en) | 2002-03-21 | 2007-12-13 | Sangamo Therapeutics, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| SG10201508995QA (en) | 2005-07-26 | 2015-11-27 | Sangamo Biosciences Inc | Targeted integration and expression of exogenous nucleic acid sequences |
| US8021867B2 (en) | 2005-10-18 | 2011-09-20 | Duke University | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
| EP3578646A3 (en) | 2007-10-31 | 2020-03-18 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| WO2011041093A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US8586363B2 (en) | 2009-12-10 | 2013-11-19 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
| WO2012138927A2 (en) | 2011-04-05 | 2012-10-11 | Philippe Duchateau | Method for the generation of compact tale-nucleases and uses thereof |
| WO2013063419A2 (en) * | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR102064230B1 (ko) * | 2013-02-15 | 2020-01-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| CN111849912B (zh) | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| AU2015276131A1 (en) | 2014-06-17 | 2016-11-17 | Cellectis | CD123 specific multi-chain chimeric antigen receptor |
| US10568947B2 (en) * | 2014-07-21 | 2020-02-25 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
| WO2016016341A1 (en) * | 2014-07-29 | 2016-02-04 | Cellectis | EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY |
| US10888608B2 (en) | 2014-09-02 | 2021-01-12 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides |
| EP3204491A1 (en) | 2014-10-07 | 2017-08-16 | Cellectis | Method for modulating car-induced immune cells activity |
| US11266739B2 (en) * | 2014-12-03 | 2022-03-08 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| IL302660B2 (en) * | 2014-12-19 | 2025-10-01 | Dana Farber Cancer Inst Inc | Chimeric antigen receptors and methods of using them |
| CN107406516B (zh) * | 2015-01-26 | 2021-11-23 | 塞勒克提斯公司 | 用于癌症免疫治疗的抗CLL1特异性单链嵌合抗原受体(scCAR) |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| AU2017338846B2 (en) * | 2016-10-04 | 2020-09-24 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
| AU2020253538A1 (en) * | 2019-04-03 | 2021-11-18 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) |
| WO2021087305A1 (en) * | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| EP4069285A1 (en) * | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells |
-
2017
- 2017-10-04 AU AU2017338846A patent/AU2017338846B2/en active Active
- 2017-10-04 WO PCT/US2017/055133 patent/WO2018067697A1/en not_active Ceased
- 2017-10-04 EP EP22172338.0A patent/EP4115951A1/en active Pending
- 2017-10-04 EP EP20176441.2A patent/EP3757120B8/en active Active
- 2017-10-04 DK DK17800638.3T patent/DK3523326T3/da active
- 2017-10-04 CA CA3039014A patent/CA3039014A1/en active Pending
- 2017-10-04 DK DK20176441.2T patent/DK3757120T3/da active
- 2017-10-04 US US16/339,699 patent/US11286291B2/en active Active
- 2017-10-04 ES ES20176441T patent/ES2925644T3/es active Active
- 2017-10-04 EP EP17800638.3A patent/EP3523326B1/en active Active
- 2017-10-04 ES ES17800638T patent/ES2811500T3/es active Active
- 2017-10-04 JP JP2019518049A patent/JP6887492B6/ja active Active
-
2019
- 2019-10-11 US US16/600,074 patent/US10800833B2/en active Active
-
2020
- 2020-09-09 US US17/016,016 patent/US20200399346A1/en not_active Abandoned
- 2020-12-11 AU AU2020286323A patent/AU2020286323B2/en active Active
-
2021
- 2021-05-18 JP JP2021083808A patent/JP7106715B2/ja active Active
-
2022
- 2022-07-13 JP JP2022112159A patent/JP2022160443A/ja active Pending
-
2023
- 2023-05-10 AU AU2023202905A patent/AU2023202905A1/en not_active Abandoned
- 2023-08-21 US US18/453,022 patent/US20240018215A1/en active Pending
-
2024
- 2024-01-31 JP JP2024013162A patent/JP2024059633A/ja active Pending
-
2025
- 2025-02-03 AU AU2025200717A patent/AU2025200717A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528769A5 (enExample) | ||
| Gao et al. | Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy | |
| Miliotou et al. | CAR T-cell therapy: a new era in cancer immunotherapy | |
| Figueroa et al. | Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy | |
| JP2017537627A5 (enExample) | ||
| Sun et al. | GARP: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasing | |
| JP2016502512A5 (enExample) | ||
| JP2017535284A5 (enExample) | ||
| JP2018029594A5 (enExample) | ||
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| JP2020022456A5 (enExample) | ||
| JP2018531014A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| IL292650B1 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| US20190000880A1 (en) | Immune effector cell therapies with enhanced efficacy | |
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| JP2016538855A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| JP2018523484A5 (enExample) | ||
| JP2017529851A5 (enExample) | ||
| JP2018509148A5 (enExample) | ||
| JP2018506981A5 (enExample) | ||
| Fang et al. | The potential regulatory roles of circular RNAs in tumor immunology and immunotherapy | |
| JP2016508725A5 (enExample) |